Spotlight Innovation Inc. (OTCMKTS:STLT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers Election of
Directors Appointment of Certain Officers Compensatory
Arrangements of Certain Officers.

On May 22, 2017, Christopher Grunewald resigned as Chief
Executive Officer of Spotlight Innovation Inc. (the Company).
Also on May 22, 2017 John Krohn was appointed Interim Chief
Executive Officer of the Company, in addition to him continuing
to serve as Chairman of the Board of Directors, President and
Chief Operating Officer of the Company. to Mr. Grunewalds
resignation, the Company issued Mr. Grunewald a warrant to
purchase 500,000 shares of Common Stock of the Corporation with
an exercise price of $1.25 per share for a term of three years.
Mr. Grunewald also agreed to cancel 1,618,627 shares of Common
Stock of the Company previously owned by Mr. Grunewald. Mr.
Grunewald will remain with the Company in an advisory capacity.

On May 24, 2017, Dr. June Beetler was appointed to the Board of
Directors of the Company. Dr. Beetler is Board Certified in
Pediatrics and has over 20 years of experience in general
practice and urgent care settings. Her experience and expertise
span general pediatrics, integrative medicine and holistic care.
She currently holds a medical license in Florida and practices at
St. Petersburg Pediatrics in St. Petersburg, Florida. Before
relocating to Florida, Dr. Beetler maintained her own practice,
Johnston Pediatric Clinic, P.C., for 18 years, and was a staff
physician at Iowa Lutheran Hospital, Iowa Methodist Medical
Center, and Mercy Medical Center – Des Moines.

About Spotlight Innovation Inc. (OTCMKTS:STLT)

Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex.

Spotlight Innovation Inc. (OTCMKTS:STLT) Recent Trading Information

Spotlight Innovation Inc. (OTCMKTS:STLT) closed its last trading session up +0.009 at 0.269 with 1,500 shares trading hands.